NCT06697301Phase 2, phase 3Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Study sponsor: Eikon Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2035-12Estimated
Enrollment · participants740Estimated
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview